TCA Cycle in the Dentate in Friedreich's Ataxia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03122925 |
Recruitment Status :
Enrolling by invitation
First Posted : April 21, 2017
Last Update Posted : March 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA).
HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label incorporation from glucose to glutamate in the brain using in vivo magnetic resonance spectroscopy.
Condition or disease | Intervention/treatment |
---|---|
Friedreich Ataxia | Device: MR |
The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA patients and in a group of age-matched healthy controls using 13C MRS in vivo together with systemic i.v. infusion of 13C-labeled glucose.
The investigators aim to obtain adequate data in 16 subjects grouped as follows:
- n=4 pilot subjects (healthy subjects) for testing and optimization of the experimental setup.
- n=6 healthy controls
- n=6 FRDA patients
In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case some subjects withdraw before completion of the MR scan, or in case the measured data are not adequate (e.g. technical problem with the scanner).
Study Type : | Observational |
Estimated Enrollment : | 20 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia |
Actual Study Start Date : | August 15, 2017 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | June 30, 2023 |

Group/Cohort | Intervention/treatment |
---|---|
Control
Healthy subjects
|
Device: MR
MR |
Friedreich's Ataxia
Diagnosed for Friedreich's Ataxia
|
Device: MR
MR |
- TCA cycle rate in the dentate nucleus [ Time Frame: Baseline ]value between 0 to 2 micromol/g/min
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- 18 years of age or older
- able to consent for themselves
- considered healthy (controls) OR be diagnosed with FRDA.
Exclusion Criteria:
- All subjects:
- Participants who cannot have an MRI, as determined by the CMRR safety screening form (e.g. metal implant)
- Pregnancy
- Clautrophobia
- Diabetes
- Clinically significant cardiac disease
Control subjects:
- Neurological disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03122925
United States, Minnesota | |
CMRR | |
Minneapolis, Minnesota, United States, 55455 |
Principal Investigator: | Pierre-Gilles Henry, PhD | University of Minnesota |
Responsible Party: | University of Minnesota |
ClinicalTrials.gov Identifier: | NCT03122925 |
Other Study ID Numbers: |
RAD-2017-25500 |
First Posted: | April 21, 2017 Key Record Dates |
Last Update Posted: | March 21, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Ataxia Cerebellar Ataxia Friedreich Ataxia Dyskinesias Neurologic Manifestations Nervous System Diseases Cerebellar Diseases Brain Diseases |
Central Nervous System Diseases Spinocerebellar Degenerations Spinal Cord Diseases Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Genetic Diseases, Inborn Mitochondrial Diseases Metabolic Diseases |